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Bacillus Calmette-Guérin Induces 
PD-L1 Expression on Antigen-
Presenting Cells via Autocrine 
and Paracrine Interleukin-STAT3 
Circuits
Alastair Copland1,3, Adam Sparrow1, Peter Hart1, Gil Reynolds Diogo1, Mathew Paul1, 
Miyuki Azuma2 & Rajko Reljic1
Bacillus Calmette-Guérin (BCG) is the only licensed vaccine for tuberculosis (TB), and is also used as an 
immunotherapy for bladder cancer and other malignancies due to its immunostimulatory properties. 
Mycobacteria spp., however, are well known for their numerous immune evasion mechanisms that limit 
the true potential of their therapeutic use. One such major mechanism is the induction of programmed 
death ligand-1 (PD-L1), which mitigates adaptive immune responses. Here, we sought to unravel 
the molecular pathways behind PD-L1 up-regulation on antigen-presenting cells (APCs) by BCG. We 
found that infection of APCs with BCG induced PD-L1 up-regulation, but that this did not depend on 
direct infection, suggesting a soluble mediator for this effect. BCG induced potent quantities of IL-6 
and IL-10, and the downstream transcription factor STAT3 was hyper-phosphorylated. Intracellular 
analyses revealed that levels of PD-L1 molecules were associated with the STAT3 phosphorylation 
state, suggesting a causal link. Neutralisation of the IL-6 or IL-10 cytokine receptors dampened STAT3 
phosphorylation and BCG-mediated up-regulation of PD-L1 on APCs. Pharmacological inhibition of 
STAT3 achieved the same effect, confirming an autocrine-paracrine cytokine loop as a mechanism 
for BCG-mediated up-regulation of PD-L1. Finally, an in vivo immunisation model showed that BCG 
vaccination under PD-L1 blockade could enhance antigen-specific memory CD4 T-cell responses. These 
novel findings could lead to refinement of BCG as both a vaccine for infectious disease and as a cancer 
immunotherapy.
The correct balance of immune effector and regulatory responses depends on a number of molecular interactions 
between the antigen-presenting cell (APC) and T-cell. A key interaction for immunological tolerance is between 
the receptors programmed death-ligand 1 (PD-L1) and programmed death-1 (PD-1). APC expression of PD-L1 
leads to binding of this molecule to PD-1 on T-cells, resulting in activation of the tyrosine phosphatase SHP-2 and 
dephosphorylation of critical kinases involved in T-cell receptor (TCR) signalling. Blockade of this interaction 
diminishes Treg frequencies1, enhances Th1 and Th17 effector cell frequencies2 and increases cytokine produc-
tion both in vitro and in vivo3. The PD-L1:PD-1 interaction has thus been targeted in immunological situations 
that feature restricted antigen presentation, T-cell anergy and immune tolerance as detrimental characteristics – 
namely chronic infectious diseases and malignancies. In the latter scenario, clinical trials have demonstrated the 
remarkable efficacy of drugs developed to target these receptors, with up to 87% clinical response rates in some 
refractory cancers4.
Worldwide, tuberculosis (TB) is the leading cause of death due to infectious disease. The only vaccine available 
is Bacillus Calmette-Guérin (BCG), which shows only modest protection in adults and alarmingly low efficacy 
in developing countries, where TB mortality is highest. BCG (like its pathogenic relative, M. tuberculosis) can 
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impede antigen presentation in vivo5,6, which is believed to contribute to the relatively low efficacy of the vaccine 
in humans. While mycobacteria-induced PD-L1 expression has been postulated as a major mechanism driving 
impaired antigen presentation7,8, it is currently not fully understood (i) the molecular mechanisms underpinning 
BCG-mediated PD-L1 up-regulation, and (ii) the immunological consequences of blocking this pathway during 
BCG immunisation.
For over 30 years, BCG has been employed as a front-line immunotherapy for bladder cancer9, and has been 
used since the late 1960s for malignant melanoma10. Although the mechanism of action remains to be completely 
elucidated, it is believed that the bacteria trigger an inflammatory response that leads to immune cell infiltra-
tion of the tumour site, thus facilitating immune-mediated clearance11. This is likely to be mediated by innate 
(i.e. Toll-like receptor) signalling, providing scope for improvement by concomitant engagement of the adaptive 
immune responses, which are known to be suppressed by PD-L1.
Here, we show for the first time that BCG can induce the up-regulation of PD-L1 on both macrophages and 
dendritic cells (DCs) via autocrine/paracrine secretion of STAT3-activating cytokines, chiefly IL-6 and IL-10. 
Blockade of the PD-L1 receptor in vivo during BCG immunisation led to superior CD4 T-cell responses to recall 
antigen, thus highlighting the potential utility of this pathway in clinical settings. These findings provide new 
targets for improving BCG as both a TB vaccine and cancer immunotherapy.
Materials and Methods
Ethics. All experiments involving live animals had full ethical approval from St George’s University ethical 
committee, under UK Home Office project license 70/7490, according to the Animals in Scientific Procedures 
Act, 1986.
Bacteria. BCG strain Pasteur was a kind gift from Professor Juraj Ivanyi (King’s College, London) and was 
grown according to previous reports12, using standard microbiological techniques. BCG expressing green fluores-
cent protein (GFP; also from the Ivanyi laboratory) was grown in identical conditions, but under selective media 
and agar containing 50 μg/mL hygromycin B (Sigma-Aldrich).
Mice and Immunisations. Female C57BL/6 mice (6 to 12 weeks old) were obtained from Charles River 
laboratories, UK. Mice were administered 1 mg of PD-L1-blocking antibody MIH513 or the rat IgG2a isotype 
control MAC21914 (kind gifts from Professor Anne Cooke, University of Cambridge) via the intraperitoneal (i.p.) 
route (day -1). Twenty-four hours later (day 0), mice received 1 × 106 CFU BCG subcutaneously (s.c.). Mice then 
received booster immunisations of MIH5 or MAC219 (1 mg per dose) on days 3, 7 and 14.
To confirm receptor blockade, mice were administered 1 mg MIH5 or MAC219 via the i.p. route, followed by 
euthanasia at 24 h, and immediate ex vivo staining of the splenocytes. Cells were stained with a reported compet-
ing fluorochrome-conjugated α-PD-L1 clone (10F.9G2)15, which binds to the same epitope as MIH5, to test for 
successful receptor blockade (Fig. 1). As an additional control for specificity, PD-L2 was also stained after MIH5 
or MAC219 treatments.
Antigen-Presenting Cell Stimulation and Infection. Bone marrow-derived DCs were obtained as 
previously described12. Cells were >90% CD11c+ by flow cytometry. DCs were stimulated in complete RPMI 
(RPMI-1640 containing 10% FCS, 2mM L-glutamine, and 50 μM β-mercaptoethanol ± 10 U/mL penicillin/strep-
tomycin – all from Sigma-Aldrich). For experiments involving macrophages, the cell line J774.1 was used, and 
cells were grown and stimulated in complete DMEM (same recipe as RPMI – Sigma-Aldrich).
For BCG infections, bacteria were washed in complete media without antibiotics, and then APCs were inocu-
lated at the designated MOI. Cells were cultured in a 5% CO2 humidified incubator at 37 °C. In some experiments, 
E. coli-derived lipopolysaccharide (LPS; Sigma-Aldrich) was used at 100 ng/mL. Cytokines (Peprotech, UK) were 
Figure 1. MIH5 blocks the PD-L1 receptor in vivo. Mice were immunised with 1 mg mAb via i.p. for 24 h 
and splenocytes were tested for blockade by staining with a fluorochrome-conjugated competitor clone. Left: 
Representative staining for PD-L1 and PD-L2. Right: Combined data from n = 2 mice per group. Bars depict 
means, dots depict individual mice.
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diluted in complete RPMI before administration. Interleukin blocking antibodies (purchased from Biolegend, 
UK) were pre-cultured with the cells for 2 h before stimulation. Stattic (Tocris Bioscience, UK) was diluted in 
DMSO (Sigma-Aldrich) and cells were treated for 2 h before infection.
Ex vivo immunogenicity assays. Spleens were aseptically removed from euthanised mice, mechanically 
homogenised and treated with ACK lysis buffer. Cells were then counted and seeded at 1.5 × 106 per well in com-
plete RPMI, followed by treatment with 10 μg/mL brefeldin A (Sigma-Aldrich). Cells were stimulated with 5 μg/mL 
Ag85B/Acr (Lionex, Germany) or PPD (NIBSC, UK) with 2 μg/mL α-CD28 (Biolegend) for 6 hours before stain-
ing for flow cytometry. PMA/ionomycin treatment (200 ng/mL and 1 μg/mL, respectively – Sigma-Aldrich) was 
used as a positive control and for staining boundaries (data not shown).
For lymph node analysis, inguinal lymph nodes were excised from euthanised mice on the indicated day, fol-
lowed by mechanical disruption, counting and immediate flow cytometric analysis.
Flow cytometry. In most experiments, cells were first washed in PBS and then incubated with 1:1000 via-
bility dye (eFluor780 Fixable Viability Dye; eBioscience) under Fc receptor blockade (1:500 TruStain; Biolegend) 
for 15–20 minutes. Cells were then washed in flow cytometry buffer (PBS (Invitrogen) containing 0.5% BSA and 
0.1% sodium azide – both from Sigma-Aldrich) and stained with the appropriate pre-titrated flow cytometry 
antibodies for 30 m at 4 °C. Cells were sometimes fixed using Biolegend Fixative Buffer before being acquired 
on a BD FACSCanto II instrument and analysed using FlowJo software. For assessing phosphorylated residues, 
cells were instead mildly fixed with Fixative Buffer for 10 m at 37 °C, and then permeabilised with a commercial 
methanol buffer (True-Phos buffer - Biolegend) for 1 hour before staining, as described elsewhere16. For intracel-
lular cytokine staining, cells were fixed with Fixative Buffer, followed by permeabilisation with flow cytometry 
buffer containing 0.5% saponin (Sigma-Aldrich). Compensation was performed using eBioscience UltraComp 
beads according to the manufacturer’s instructions. Antibodies used were PD-L1-Brilliant Violet 421, PD-L2-PE, 
CD11c-PerCP/Cy5.5, CD3ε-FITC, CD4-PerCP/Cy5.5, CD8α-Brilliant Violet 510, IL-2-PE, IL-17A-PE/Cy7, 
IFN-γ-Brilliant Violet 421, MHC Class II- Brilliant Violet 510, TNF-α-APC and p-STAT3-Alexa Fluor 647. All 
antibodies were purchased from Biolegend, UK unless otherwise specified.
Enzyme-linked immunosorbent assay. Cytokine levels in supernatants were measured using eBiosci-
ence Ready-Set-Go ELISA kits, according to the manufacturer’s instructions. Plates were read at 482 nm on a 
Tecan200 plate reader.
Statistical analysis. For all experiments, statistical tests were performed with Microsoft Excel and GraphPad 
Prism software, using averaged technical replicates where possible. Each statistical test and post-test is detailed in 
the relevant figure legends. A p value less than 0.05 was considered significant.
Results
BCG Induces Up-regulation of PD-L1 Expression on both Macrophages and Dendritic Cells. 
DCs and macrophages are critical for the initiation of adaptive immunity. BCG can induce the up-regulation 
of PD-L1 expression on pulmonary DCs in mice7, however it is unclear whether the same holds true for mac-
rophages. DCs and macrophages were therefore infected with BCG over a range of multiplicities of infection 
(MOI) and across two time-points (24 h and 48 h); surface expression of PD-L1 was assessed by flow cytome-
try. As shown in Fig. 2A, the positive control lipopolysaccharide (LPS) was able to significantly increase PD-L1 
expression on both cell types (p < 0.0001), with a striking >10 fold increase in macrophages at 48 h. Upon infec-
tion with BCG, both APC types expressed high levels of PD-L1 compared to the unstimulated control at 24 h and 
48 h (p < 0.0001), and a dose trend was observed for increasing MOI in macrophages at 48 h.
Next, a transgenic strain of BCG that expresses green fluorescent protein (GFP) was used to determine 
whether the up-regulation of PD-L1 depended on direct interaction between APCs and the bacteria. Cells were 
gated by GFP fluorescence into GFPneg (i.e. “bystander”) and GFPpos (i.e. infected) populations. These were then 
tested for PD-L1 expression. As anticipated, GFPpos infected cells displayed increased expression of PD-L1 that 
was proportionate to the infectious dose (Fig. 2B). Surprisingly, however, GFPneg bystander cells also exhibited 
similar dose-dependent increases in PD-L1 expression to GFPpos cells, which was significantly up-regulated com-
pared to the uninfected control at the highest MOI (p < 0.05), and approximately 80% that of directly infected 
cells. In support of these observations, 0.2 µm filtration of BCG infection supernatants, when applied to new 
cells, was able to up-regulate PD-L1 (Supplementary Fig. 1). As expected, control supernatants from uninfected 
cells did not affect PD-L1 expression. These data strongly suggested that a soluble, secreted factor in culture was 
driving PD-L1 up-regulation by BCG.
Interestingly, BCG was able to up-regulate other members of the B7 family (CD80, CD86, PD-L2) to a certain 
degree, but with a pattern of skewed up-regulation of PD-L1 compared to CD86 (Supplementary Fig. 2).
BCG Induces IL-6 and IL-10 Production in tandem with STAT3 Phosphorylation. The murine 
PD-L1 gene (Cd274) is under the control of complex regulatory networks and can be induced by a number of 
inflammatory cytokines or TLR ligands17. Many of these control mechanisms are cell type-specific. Since myco-
bacteria are adept at driving STAT3 activation18, and since STAT3 is capable of binding to the PD-L1 promoter in 
tolerogenic DCs19, we hypothesised that this signalling pathway was mediating the observed effects of infection.
DCs and macrophages were infected for 18 h and intracellular flow cytometry was used to determine 
the levels of STAT3 tyrosine residue 705 phosphorylation. As can be observed in Fig. 3A, BCG was able to 
hyper-phosphorylate the STAT3 transcription factor compared to unstimulated cells (p < 0.001). Notably, there 
was a trend for increased phosphorylation when comparing BCG to the positive control LPS. We next hypothe-
sised that APCs were producing STAT3-activating cytokines. STAT3 can be activated weakly by IL-2 and IL-12, 
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but strongly by prototypical myeloid-type cytokines such as IL-6 and IL-10. APCs were therefore infected with 
BCG (or stimulated with LPS) for 24–48 h and levels of IL-6 and IL-10 were measured by ELISA. BCG was found 
to induce potent quantities of IL-6 in both DCs and macrophages at a range of MOI (Fig. 3B; p < 0.0001 BCG 
vs unstimulated cells). BCG elicited IL-10 in both cell types. Strikingly, with regards to IL-10 production, BCG 
greatly surpassed the ability of LPS at MOI = 2, with over 4-fold concentrations of this cytokine compared to the 
positive control.
PD-L1 Expression Correlates with STAT3 Phosphorylation. With the hypothesis that BCG was 
inducing STAT3-activating cytokines to up-regulate PD-L1, we treated DCs and macrophages with different 
concentrations of IL-6 and IL-10 and measured PD-L1 up-regulation by flow cytometry. In DCs (Fig. 4A), IL-6 
played a dominant role in the up-regulation of PD-L1 expression compared to IL-10. When both cytokines were 
used in combination, there was only a marginal increase above the levels of PD-L1 expression conferred by IL-6. 
In macrophages, by contrast, IL-6 and IL-10 behaved similarly in terms of receptor up-regulation, and there was a 
combinatorial effect that was clearly evident at 500 pg/mL. For both cell types, there was a dose-dependent effect, 
with 500 pg/mL of any cytokine (or combination) being superior to 50 pg/mL in up-regulating PD-L1 expression.
Next, macrophages were infected with BCG for 18 h and cells were then permeabilised as before and 
co-stained for p-STAT3 and PD-L1. Cells were then divided into PD-L1lo and PD-L1hi populations and then 
Figure 2. BCG can up-regulate PD-L1 expression without direct cellular association. DCs and macrophages 
were infected in duplicate with BCG and PD-L1 expression was assessed by flow cytometry. (A) Left: 
Representative staining of PD-L1 on macrophages at 48 hours. Cells were gated by size and then viability. 
Numbers denote median fluorescence intensity (MFI). Right: PD-L1 expression on DCs and macrophages 
infected with 0.1–2 MOI BCG or stimulated with 100 ng/mL LPS, at 24 h and 48 h post-infection. (B) 
Macrophages were infected with BCG expressing GFP for 24 h. Top: Gates were set on the negative control 
to determine GFPneg and GFPpos populations. Bottom left: Representative histograms depicting PD-L1 
expression in GFPneg and GFPpos cells. Bottom right: Pooled data showing PD-L1 MFI in infected and bystander 
macrophages. Significance was tested against the negative control by two-way ANOVA with Dunnett’s post-test 
(A,B). Bars depict means ± SEM. Data derived from n = 3 experiments: ****p < 0.0001. *p < 0.05.
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levels of p-STAT3 were quantified. As shown in Fig. 4B, PD-L1lo cells exhibited significantly lower levels of STAT3 
phosphorylation compared to their PD-L1hi counterparts (p < 0.05), with a doubling of fluorescence intensity in 
some experiments. Taken together, these data suggested that BCG was utilising interleukin signalling pathways 
in order to up-regulate expression of PD-L1.
IL-6R/IL-10R Blockade or STAT3 Inhibition Leads to Impeded PD-L1 Up-regulation by BCG. We 
next questioned whether direct intervention in the interleukin-STAT3 axis could revert the up-regulation of 
PD-L1 by BCG. To this end, we employed a combination of monoclonal antibodies (mAbs) that are known to 
block the IL-6 and IL-10 cytokine receptors, alongside the pharmacological inhibitor ‘Stattic’: a well-characterised 
and highly specific small-molecule inhibitor of STAT3 transcriptional activity20.
To test whether neutralising the biological activities of endogenous cytokines could reduce the increase in 
PD-L1 expression caused by BCG, cells were first pre-incubated under IL-6R (mAb D7715A7) or IL-10R (mAb 
1B1.3a) blockade, or a combination of both, for 2 h. Isotype controls served as controls for non-specific activity. 
Cells were then infected with BCG and after 24 h, PD-L1 expression was determined (Fig. 5A). Both IL-6 and 
IL-10 blockade significantly reduced PD-L1 expression (p < 0.001) compared to the isotype control baseline. 
As expected, the combination of blocking both receptors led to the greatest reduction in PD-L1 fluorescence 
(~40–45%; p < 0.0001 vs isotype control). In keeping with the hypothesised role of STAT3 in BCG-induced 
PD-L1 expression, blockade of both receptors also led to a large reduction in STAT3 phosphorylation, as shown 
in Fig. 5B (BCG + isotype MFI: 5416; BCG + dual blockade MFI: 2911).
To confirm that STAT3 was mediating the up-regulation of PD-L1 expression by BCG, cells were then 
pre-treated with Stattic or a vehicle control for 2 hours before infection with a low dose of bacteria (Fig. 5C). 
LPS served as a positive control, since it can induce PD-L1 expression via this pathway21. After 24 hours, the cells 
treated with 5 μM Stattic and infected with BCG showed a dramatically reduced expression level of PD-L1 com-
pared to those treated with a vehicle control (p < 0.05), with an near-100% reduction in PD-L1 expression. Similar 
results were observed for LPS. Strikingly, resting cells treated with Stattic actually increased PD-L1 expression 
compared to the vehicle control, although this was a non-significant trend with high variation. Collectively, these 
data proved that BCG could modulate PD-L1 expression by interleukin-STAT3 signalling circuits.
In vivo PD-L1 Blockade Augments Antigen-Specific Memory CD4 T-cell Responses. A 
proof-of-principle in vivo immunogenicity assay was next performed in order to establish that targeting the 
PD-L1 receptor during BCG immunisation could lead to increased T-cell function. A cytokine panel spanning 
Figure 3. BCG induces STAT3 activation and secretion of STAT3-activating interleukins. (A) Macrophages 
were infected in duplicate for 18 h with 0.1 MOI BCG or 100 ng/mL LPS. Cells were stained for surface PD-L1 
expression, followed by intracellular staining for p-STAT3. Top: Representative histogram showing levels 
of STAT3 phosphorylation. Numbers denote MFI. Bottom: Pooled data from several experiments showing 
p-STAT3 MFI. (B) DCs and macrophages were infected in duplicate with 0.1–2 MOI BCG or 100 ng/mL LPS for 
24–28 h and supernatants were tested for IL-6 and IL-10 by ELISA. Significance was tested by one-way ANOVA 
with Tukey’s post-test (A) or two-way ANOVA with Dunnett’s post-test against the negative control (B). Data 
are derived from n = 3 experiments. Bars depict means ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01.
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several hallmark Th1/Th17 cytokines (IFN-γ, IL-2, IL-17A, TNF-α) was used to determine T-cell reactogenicity 
in a vaccination model with recall mycobacterial antigens (Fig. 6A).
First, the up-regulation of PD-L1 in vivo was determined by sub-cutaneous immunisation with BCG followed 
by characterisation of PD-L1 expression in the draining lymph nodes (Supplementary Fig. 3). It was found that 
BCG was able to up-regulate PD-L1 in MHC Class IIhigh CD11c+ DCs, but unable to do the same in T-cells, con-
firming a specific effect in APCs. Next, mice were treated with 1 mg of the PD-L1 blocking antibody MIH5 via 
the intraperitoneal route, followed by immunisation with subcutaneous BCG. Mice were then given follow-up 
booster immunisations to maintain the PD-L1 blockade. An isotype control was used at the same concentration 
to control for non-specific effects. On day 21, splenocytes from immunised mice were then pulsed with either 
immunodominant and latency-associated antigens (Ag85B and Acr, respectively) or a mixture of protein antigens 
(PPD). As shown in Fig. 6B, there was a general trend for an increase in antigen-specific cytokine production 
in CD4 T-cells. Under PD-L1 blockade, BCG induced significantly more IFN-γ in response to Ag85B/Acr and 
PPD (IFN-γ: p < 0.0001), compared to the isotype control. TNF-α production was also increased in response to 
Ag85B/Acr (p < 0.01). Regarding IL-2 and IL-17A, there were non-significant increases caused by PD-L1 block-
ade under both antigen recall conditions.
Turning our attention to the CD8 T-cell compartment (Fig. 6C), we found that BCG was much poorer at 
inducing antigen-specific cytokine responses, as has been observed previously by others22. With the exception of 
IL-2 after Ag85B/Acr pulsing (p < 0.05), splenocytes from mice that received BCG + isotype control were unable 
to produce more cytokines than splenocytes from mock-immunised mice. Only two cytokines were found to 
be increased by PD-L1 blockade beyond the PBS control group in response to Ag85B/Acr but not PPD: IFN-γ 
(p < 0.01) and TNF-α (p < 0.01), however these effects were marginal. Thus we concluded that PD-L1 block-
ade can effectively boost CD4-dependent T-cell immunity, with only marginal effects on boosting CD8 T-cell 
responses.
Discussion
It is long-recognised that bacteria (and indeed other pathogens) belonging to genetically distinct phyla are capable 
of modulating the repertoire of co-stimulatory and co-inhibitory molecules expressed on the APC surface23, thus 
affirming the critical importance of said receptors in the directing of adaptive immune responses. Mycobacteria 
represent an example of immune evasion par excellence due to their ancient history of co-evolution with mamma-
lian immune systems24; indeed, virtually all pathogenic mycobacteria are obligate parasites, requiring intracellular 
Figure 4. IL-6 and IL-10 are sufficient for PD-L1 expression and STAT3 is associated with its expression.  
(A) DCs and macrophages were stimulated with 50 or 500 pg/mL recombinant IL-6, IL-10 or both for 24 h and 
PD-L1 expression was assessed by flow cytometry. Representative histograms are depicted with MFIs for the 
relevant conditions, alongside pooled data from multiple experiments. (B) Macrophages were infected with 0.1 
MOI BCG for 18 h and p-STAT3 was analysed by flow cytometry. Left: Representative histogram with MFIs and 
gating strategy, showing p-STAT3 analysis within PD-L1lo and PD-L1hi populations. Right: Pooled data from 
multiple experiments. Data are derived from n = 3 experiments (A, B). Significance was tested by student’s t-test 
(B). Bars depict means ± SEM. *p < 0.05.
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resources in order to thrive and propagate. It is therefore not surprising that they are biologically equipped to 
effectively counter adaptive immune responses that would lead to their own clearance.
A centrally important molecule in the control of T-cell immunity is PD-L1. Mice infected with mycobacteria 
harbour pulmonary DCs that express high levels of PD-L1 and restrict antigen presentation to CD4 T-cells25, 
and PD-L1 blockade in blood and lung lavage from TB patients can enhance responses to Mtb antigens, as seen 
by greater cytokine production and T-cell proliferation26,27. Furthermore, PD-L1 blockade is able to rescue these 
cells from functional exhaustion, as demonstrated by the reversal of T-cell apoptosis28. For bladder cancer, the 
tumour surface is reportedly decorated with high levels of PD-L1 molecules, and the tumour-infiltrating B- and 
T-cells express high levels of both PD-L1 and PD-129,30. The utilisation of BCG as a prophylactic (TB) or thera-
peutic (malignancy) treatment for these diseases, combined with a strategy to mitigate the effects of PD-L1, could 
provide a strong advantage for the efficacy of BCG.
In this study, for the first time, it was shown that BCG drives up-regulation of PD-L1 expression on APCs by 
autocrine/paracrine cytokine circuits that lead to STAT3 phosphorylation and up-regulation of this co-inhibitory 
receptor (illustrated in Fig. 7). It has been known for some time that BCG is a strong inducer of these cytokines 
via rudimentary TLR signalling, however it was not known that they were driving PD-L1 expression in a biphasic 
response. The observation that inhibition of STAT3 did not lead to a decrease in PD-L1 expression in resting 
cells—indeed, there was instead a non-significant increase in expression—is consistent with the notion that the 
PD-L1 gene promoter requires distinct transcriptional apparatus during the steady-state and during active infec-
tion. This is in accord with the fact that DCs and macrophages displayed moderate levels of constitutive PD-L1 
expression in the absence of any appreciable cytokine levels31. Physiologically, this is undoubtedly to prevent 
spontaneous activation of the adaptive immune system.
Using the mAb MIH5, we were able to neutralise most of the PD-L1 receptor in vivo and augment the quan-
tities of cytokine produced by CD4 T-cells in response to recall antigen in a proof-of-principle experiment. It is 
interesting to note that PD-L1 blockade in vivo did not greatly boost the antigen-specific CD8 T-cell responses 
beyond that of the mock-immunised control group. BCG is widely known to only minimally induce cytotoxic 
T-cell responses, with a strong bias towards CD4 responses22. This may be due to so-called CD8 ‘decoy antigens’, 
such as TB10.4, that serve to divert responses away from immunogenic epitopes for cytotoxic T-cells32. Whether 
the enhancement of CD4 T-cell immunogenicity in the absence of strong CD8 T-cell immunogenicity leads to 
better vaccine (i.e. in the case of TB) or immunotherapeutic (i.e. in the case of a carcinoma) outcomes warrants 
testing in disease-specific animal models.
Figure 5. BCG-mediated up-regulation of PD-L1 is diminished by inhibiting the interleukin-STAT3 axis.  
(A) Macrophages were pre-treated with 50 μg/mL blocking antibodies or isotype controls for ~2 h and infected 
with 0.1 MOI BCG for 24 h. PD-L1 expression was measured by flow cytometry. Left: Representative histogram 
of PD-L1 expression with MFIs depicted. Right: Pooled data from multiple experiments, with calculated 
percentage reduction in PD-L1 MFI. (B) Macrophages were pre-treated with 50 μg/mL IL-6R and IL-10R 
blocking antibodies and then infected with 0.1 MOI BCG for 18 h. Levels of p-STAT3 were determined by 
intracellular flow cytometry. Shown is a representative plot with depicted MFI for p-STAT3. (C) Macrophages 
were pre-treated with the indicated dose of Stattic or DMSO equivalent for 2 hours, and then infected with 0.1 
MOI BCG or stimulated with 100 ng/mL LPS for 24 h. Levels of PD-L1 were measured by flow cytometry. Left: 
Representative histogram showing Stattic-mediated PD-L1 down-regulation. Right: Pooled data from multiple 
experiments showing percentage change from the vehicle control. Significance was tested by one-way ANOVA 
with Tukey’s post-test (A) or two-way ANOVA with Dunnett’s post-test vs the vehicle control (B). Bars depict 
means ± SEM. Data are derived from n = 3 experiments. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05.
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An important limitation of this study is that IL-6 and IL-10 are unlikely to constitute the only two cytokines 
driving the STAT3-PD-L1 pathway, and we expect that there is redundancy in which cytokine drives PD-L1, as 
long as STAT3 is adequately activated. STAT3 can also be activated by nearly 20 members of the IL-6 and IL-10 
cytokine families. However, IL-6 and IL-10 are two of the most abundant cytokines secreted by myeloid cells upon 
activation, and while dual blockade of the receptors led to a ~45% reduction in PD-L1, this could reflect the fact 
that blocking antibodies do not completely neutralise all biological activity33. STAT3 can also be weakly activated 
by TLR signalling and Src-family kinases34,35, and we cannot exclude the possibility of such contributions to 
its phosphorylation state. Furthermore, there are undoubtedly other transcriptional co-factors recruited to the 
Cd274 promoter alongside STAT3. Regardless, we have conclusively shown that STAT3 is biologically essential for 
its activity by BCG, and linked this to biological targets that are amenable to intervention in clinical settings (e.g. 
tocilizumab, an α-IL-6R mAb). Indeed, this study provides four such points of intervention when using BCG: (i) 
Figure 6. In vivo PD-L1 blockade during BCG immunisation boosts CD4 T-cell cytokine production. 
Splenocytes from immunised mice were cultured in duplicate with 2 μg/mL α-CD28 and either Ag85B/Acr 
(5 μg/mL) or PPD (5 μg/mL) for 6 hours, in the presence of brefeldin A (10 μg/mL). (A) Cells were then stained 
for Th1-Th17 cytokines and gated by size/viability → CD3+  → CD4+/CD8+. (B) CD4 T-cell cytokine responses. 
(C) CD8 T-cell cytokine responses. Significance was tested by two-way ANOVA with Dunnett’s post-test. Data 
are derived from n = 3 mice per group. Bars depict means ± SEM. ****p < 0.0001, ***p < 0.001, **p < 0.01, 
*p < 0.05.
Figure 7. Model for BCG-mediated up-regulation of PD-L1 expression. Proposed schematic showing how 
BCG targets IL-6 and IL-10 to cause STAT3 phosphorylation and PD-L1 up-regulation.
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STAT3-activating cytokines, (ii) IL-6/IL-10 cytokine receptors, (iii) the STAT3 transcription factor and (iv) the 
PD-L1 receptor itself.
STAT3 presents a highly appealing therapeutic target other than its role in PD-L1 expression due to the fact 
that is a pleiotropic master controller of general tolerance in APCs. STAT3 can suppress autophagy36, nitric oxide 
production37, IL-12 production38, and co-stimulatory molecule expression39. Given our new findings, targeting 
this pathway during vaccination with BCG (for TB or malignancy) could reap multiple therapeutic benefits.
In conclusion, we have revealed novel molecular insights into how BCG up-regulates PD-L1 on APCs, allow-
ing for improved immunogenicity to specific antigens, but also more intricate understanding of fundamental 
host-pathogen interactions. Future work will focus on exploring this pathway in specific disease models that rely 
on BCG as a treatment, with the aim of bolstering immunological parameters, and ultimately, treatment efficacy.
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